- Investing.com
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Financial Outlook | Cash runway into 2026, but elevated R&D spending raises concerns. Analysts set price targets ranging from $1.00 to $10.00 |
R&D Progress | KOURAGE 1 Phase 3 trial results expected Q2 2024, potentially accelerating the 2027 launch timeline and 50% probability of approval estimate |
Market Opportunity | Analysts project peak sales of $630 million by 2035 for oral DFK in NP, with limited competition providing potential first-mover advantage |
Strategic Pivot | Cara Therapeutics narrows focus to oral difelikefalin for notalgia paresthetica, aiming to capitalize on high unmet need and promising Phase 2 data |
Metrics to compare | CARA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCARAPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −3.1x | −0.6x | |
PEG Ratio | −0.01 | −0.02 | 0.00 | |
Price / Book | 30.1x | 0.1x | 2.6x | |
Price / LTM Sales | 2.4x | 4.4x | 3.1x | |
Upside (Analyst Target) | 160.6% | 185.4% | 53.6% | |
Fair Value Upside | Unlock | 2.6% | 8.0% | Unlock |